Does classical immunity acquired by the subcontinent population become advantageous to manage COVID-19 due to the low rate of mortality?
Crossref DOI link: https://doi.org/10.17352/ojbs.000022
Published Online: 2020-06-23
Update policy: https://doi.org/10.17352/crossmark-policy
Partha Pratim, Das https://orcid.org/0000-0003-3871-1628
Subhash, Medhi
Sangit, Dutta
Pranab Jyoti, Das
